

Human BTN3A2 Protein

Cat. No. BNT-HM4A2

Description

Source	Recombinant Human BTN3A2 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gln30-Trp248.
Accession	P78410-1
Molecular Weight	The protein has a predicted MW of 26.5 kDa. Due to glycosylation, the protein migrates to 27-33 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 $\mu\text{g}/\text{ml}$ is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC). In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.


Assay Data

Bis-Tris PAGE



Human BTN3A2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human BTN3A2 is greater than 95% as determined by SEC-HPLC.